Literature DB >> 1371493

Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons.

R A June1, A L Landay, K Stefanik, T F Lint, G T Spear.   

Abstract

While expression of complement receptor 2 (CR2) (CD21) on some CD4+ cell lines renders them more susceptible to infection by complement-treated human immunodeficiency virus (HIV), coexpression of CR2 and CD4 on peripheral blood lymphocytes has not, until recently, been observed. Several recent studies, however, have found that human T lymphocytes express low levels of CR2. Additionally, complement treatment of HIV before addition to these cells has been reported to increase virus expression in peripheral blood lymphocyte cultures. These findings suggest that complement-mediated enhancement of infection of human T cells could occur in vivo and have prompted us to examine both the phenotypic properties of CD4+CR2+ T cells in healthy persons and the expression of CR2 on CD4+ lymphocytes during HIV infection. As was previously reported, we observed CR2 on a proportion (10-50%) of both CD8+ and CD4+ T cells. Approximately half of CD4+CR2+ cells expressed the memory cell markers CD45RO and CD29, 80% expressed the naive marker CD45RA, while 22% expressed CD25. These values were not substantially different from total CD4+ cells. Stimulation of lymphocytes with phytohaemagglutinin (PHA), OKT3 or calcium ionophore but not with phorbol myristate acetate (PMA) or interleukin-2 (IL-2) decreased expression of CR2 on CD4 cells by half over a 3-day culture period. The per cent of CD4+ cells expressing CR2 was significantly decreased in patients with asymptomatic and symptomatic HIV infection compared to uninfected control donors (P = 0.0001). In contrast, the decrease in CR2 expression was not observed with CD8+ lymphocytes from HIV-infected persons. These results confirm that CR2 is expressed on human T lymphocytes and suggest that a subset of CD4+ lymphocytes is selectively affected in HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371493      PMCID: PMC1384803     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

1.  Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes.

Authors:  E Fischer; C Delibrias; M D Kazatchkine
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

2.  Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation.

Authors:  R A June; S Z Schade; M J Bankowski; M Kuhns; A McNamara; T F Lint; A L Landay; G T Spear
Journal:  AIDS       Date:  1991-03       Impact factor: 4.177

3.  Characterization of monoclonal antihuman-B-cell antibody BL13 as an anti-C3d-receptor (CR2) antibody.

Authors:  J H Cohen; E Fischer; M D Kazatchkine; J Brochier; J P Revillard
Journal:  Scand J Immunol       Date:  1986-03       Impact factor: 3.487

4.  Phenotypic changes associated with activation of CD45RA+ and CD45RO+ T cells.

Authors:  D L Wallace; P C Beverley
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

Review 5.  Complement ligand-receptor interactions that mediate biological responses.

Authors:  D T Fearon; W W Wong
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

6.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.

Authors:  J P Van Wauwe; J R De Mey; J G Goossens
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

7.  Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals.

Authors:  S M Schnittman; H C Lane; J Greenhouse; J S Justement; M Baseler; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

8.  Phenotypical and functional differentiation of CD4+ CD45RA+ human T cells following polyclonal activation.

Authors:  K Kristensson; M Dohlsten; H Fischer; P O Ericsson; G Hedlund; H O Sjögren; R Carlsson
Journal:  Scand J Immunol       Date:  1990-09       Impact factor: 3.487

9.  A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

10.  Glomerular lesions in the acquired immunodeficiency syndrome.

Authors:  V Pardo; M Aldana; R M Colton; M A Fischl; D Jaffe; L Moskowitz; G T Hensley; J J Bourgoignie
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

View more
  7 in total

1.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

Review 2.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Ablation of the cellular prion protein, PrPC, specifically on follicular dendritic cells has no effect on their maturation or function.

Authors:  Laura McCulloch; Karen L Brown; Neil A Mabbott
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

4.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

5.  Complement activation by human monoclonal antibodies to human immunodeficiency virus.

Authors:  G T Spear; D M Takefman; B L Sullivan; A L Landay; S Zolla-Pazner
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

6.  Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection.

Authors:  O Lund; J Hansen; A M Søorensen; E Mosekilde; J O Nielsen; J E Hansen
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

7.  Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.

Authors:  Suzanne Willey; Marlén M I Aasa-Chapman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Robin A Weiss; Stuart J D Neil
Journal:  Retrovirology       Date:  2011-03-14       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.